For decades, India’s life sciences identity has rested on a formidable but ultimately derivative foundation—generics, contract manufacturing, and vaccine production delivered at a scale and cost efficiency that the world has come to rely upon. That foundation remains commercially indispensable. What is shifting, with gathering momentum, is the ambition layered above it. Biologics and advanced […]
A decade ago, India’s bioeconomy was valued at $10 billion. Today it stands at $165 billion. The question is no longer whether India can compete globally in biotechnology—it is whether the country can build the institutional architecture to lead it. India’s transformation into a serious biotech contender has unfolded with a speed that has surprised
From Academic Foundations to Applied Intelligence: Dr. Murali Addepalli’s Journey in Advancing Biologics Toward Patient CareWork across NIH research, industry biologics programs, and emerging AI applications in drug discovery. Most researchers dream of discovering breakthrough therapies. Dr. Murali Addepalli set himself a different, more audacious goal: actually, getting one to patients. Not publishing elegant papers about potential therapeutics that remain trapped in
From IIT Bombay to continuous manufacturing platforms—how one leader’s 18-year journey across Amgen, Regeneron, and Indian biotech is redefining what’s possible in biologics development Most biotechnology leaders pick a lane: deep technical expertise or broad operational leadership, Big Pharma scale or biotech agility, innovator molecules or biosimilars execution. Dr. Abhishek Mathur has systematically refused to
How two decades in biologics development shaped an unconventional academic career focused on teaching students what actually happens beyond the textbook Most academics transition from university research into industry positions seeking bigger budgets, faster timelines, and commercial impact. Dr. Samir Kulkarni took the opposite path—and it wasn’t planned. After nearly 20 years in senior leadership
Few moments in modern pharmaceutical history carry the democratising force of a blockbuster patent expiry, and March 2026 is shaping up to be one of the most consequential in India’s medical landscape. On 20 March, semaglutide — the GLP-1 receptor agonist powering Novo Nordisk’s Ozempic and Wegovy franchises and widely regarded as the most transformative
A single executive appointment rarely signals a geopolitical shift. Yet when Daiichi Sankyo announced on 24 February 2026 that Dr Yuki Kondo — former Merck Japan president and architect of Keytruda’s blockbuster regional ascent — would assume its oncology Chief Marketing Officer role, the announcement carried a weight far beyond the usual C-suite reshuffle. It
What takes ten years and costs $2 billion? Until recently, developing a single new drug molecule. What now takes months and costs a fraction of that? The same process powered by artificial intelligence platforms that Hyderabad‘s Genome Valley startups are wielding to transform India from the world’s pharmacy into a genuine innovation hub. At BioAsia
AI Meets Biologics: How India Plans to Reinvent Itself Beyond Generic Drugs Read More »
Finance Minister Nirmala Sitharaman‘s February 1, 2026, Union Budget contained a declaration of pharmaceutical ambition that industry leaders are calling transformative: Biopharma Shakti, a ₹10,000 crore five-year initiative designed to vault India from its established position as the world’s generics pharmacy—commanding 20% of global volume in small-molecule drugs—toward the technically demanding and far more lucrative
Finance Minister Nirmala Sitharaman‘s February 1, 2026, Union Budget delivered what pharmaceutical industry leaders are already calling a “defining moment”—Biopharma Shakti, a ₹10,000 crore five-year initiative designed to catapult India from its comfortable position as the world’s generics pharmacy commanding 20% global volume toward the far more lucrative and technically demanding frontier of biologics and
India Just Bet ₹10,000 Crore That It Can Beat the World at Making Biologic Drugs Read More »
